King's College London

Research portal

Diagnostic and clinical utility of antibodies against the nuclear body promyelocytic leukaemia and Sp100 antigens in patients with primary biliary cirrhosis

Research output: Contribution to journalArticle

Maria G. Mytilinaiou, Wolfgang Meyer, Thomas Scheper, Eirini I. Rigopoulou, Christian Probst, Andreas L. Koutsoumpas, Daniel Abeles, Andrew K. Burroughs, Lars Komorowski, Diego Vergani, Dimitrios P. Bogdanos

Original languageEnglish
Pages (from-to)1211-1216
Number of pages6
JournalClinica Chimica Acta
Issue number15-16
Publication statusPublished - 16 Aug 2012

King's Authors


Background: The lack of an immunoassay that detects antibodies to promyelocytic leukaemia (PML) protein, the primary biliary cirrhosis (PBC)-specific multiple nuclear dot (MND) antigen, has prompted us to develop a line immunoassay (LIA) for the simultaneous detection of PML and Sp100 MND-specific autoantibodies.

Methods: PML and Sp100 were expressed in Escherichia coli, and analysed by SOS-PAGE and immunoblotting using a monoclonal antibody and MALDI-ToF fingerprinting. A. quantitative PML and Sp100 LIA were developed and testing was performed in 150 anti-mitochondrial antibody (AMA) positive, 20 AMA-PBCs and 130 controls.

Results: Thirty-five (23%) of 150 AMA + PBCs (18 anti-MND+) were anti-PML+ (12%) or anti-Sp100+ (20%). 10 being anti-PML+/Sp100+, 5 single anti-PML+ and 20 single anti-Sp100+. Six (30%, 5 anti-MND+) AMA-PBCs were anti-PML+ or Sp100+. Only 2 (1.7%) pathological controls were anti-PML+ and/or anti-Sp100+. Levels of anti-PML correlated with those of anti-Sp100 (R = 0.64, p<0.0001). The autoantibody profile largely remained unchanged over a 10 year-follow up (52 patients, 352 samples). Anti-PML, Sp100 or MND-reactive PBCs were younger and had longer disease duration than the seronegative (p = 0.06, for both). Anti-Sp100 levels correlated with the Mayo risk score (r = 0.63, p = 0.01). Anti-PML+/Sp100+ patients had more advanced disease compared to patients negative for anti-PML/Sp100 (p = 0.04).

Conclusion: The new line immunoassay offers a robust and accurate method for the detection of clinically-relevant PBC-specific anti-MND antibodies. (C) 2012 Elsevier B.V. All rights reserved.

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454